预约演示
更新于：2025-05-16
Lamivudine/Zidovudine
齐多拉米双夫定
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-09-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H24N8O7S |
InChIKeyLHCOVOKZWQYODM-CPEOKENHSA-N |
CAS号165456-81-5 |
关联
74
项与 齐多拉米双夫定 相关的临床试验CTR20222542
齐多拉米双夫定片在中国健康受试者中空腹及餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉设计生物等效性试验。
CTR20192017
齐多拉米双夫定片在中国健康受试者单次、空腹及餐后、随机开放、两制剂、三周期三序列三交叉生物等效性试验
CTR20190551
齐多拉米双夫定片在中国健康受试者中随机、开放、空腹及餐后、单剂量、两周期、双交叉生物等效性试验
100 项与 齐多拉米双夫定 相关的临床结果
登录后查看更多信息
100 项与 齐多拉米双夫定 相关的转化医学
登录后查看更多信息
100 项与 齐多拉米双夫定 相关的专利（医药）
登录后查看更多信息
246
项与 齐多拉米双夫定 相关的文献（医药）2022-11-18ChemistrySelect
作者: Tilkan, M. Günseli ; Büker, Eda ; Hoang, Vu Dang ; Özdemir, Nurten ; Dinç, Erdal ; Rouhani, Ghazal
Abstract:
Classical and chemometric calibration strategies based‐Ultra Performance Liquid Chromatography‐Photodiode Array (UPLC‐PDA) measurements were improved to monitor the in‐vitro dissolution profiles of lamivudine (LAM) and zidovudine (ZID) in tablets and to quantify drugs. To generate UPLC‐PDA data, UPLC analysis was done using the mobile phase containing acetonitrile‐acetate buffer pH 5.0 (18 : 82, v/v). In the classical strategy, calibration curves were obtained by using the peak area ratios detected at 274 nm for LAM and 268 nm for ZID, respectively. Principal component regression (PCR) and partial least squares (PLS) strategies were used to solve the same problem using UPLC‐PDA measurements obtained at eight different wavelengths. Both classical and chemometric approaches were successfully applied for drugs assay and in‐vitro dissolution testing. Assay results showed that the proposed chemometric tools gave better results because they helped to minimize the effect of chromatographic issues that commonly occur with the classical UPLC approach, such as the higher standard deviation of the assay results.
2019-10-29mBio
CD161
+
CD4
+
T Cells Harbor Clonally Expanded Replication-Competent HIV-1 in Antiretroviral Therapy-Suppressed Individuals
Article
作者: Li, Linghua ; Deng, Kai ; Huang, Zhuoqiong ; Gao, Hongbo ; Cai, Weiping ; Zhao, Lu ; Hu, Ronglin ; Liu, Zhaoli ; Zhao, Jiacong ; Li, Xiaomin ; Li, Qijuan ; Yang, Yanyan
The latent reservoir continues to be the major obstacle to curing HIV-1 infection. The clonal expansion of latently infected cells adds another layer maintaining the long-term stability of the reservoir, but its mechanism remains unclear. Here, we report that CD161
+
CD4
+
T cells serve as an important compartment of the HIV-1 latent reservoir and contain a significant amount of clonally expanded proviruses. In our study, we describe a feasible strategy that may reduce the size of the latent reservoir to a certain extent by counterbalancing the repopulation and dissemination of latently infected cells.
2019-04-01Antiviral therapy4区 · 医学
4区 · 医学
Article
作者: McDonald, Grainne ; Jackson, Valerie ; Lambert, John S ; Redmond, Niamh ; Else, Laura J ; Kuan, Kenneth BK ; Avramovic, Gordana ; Murtagh, Ross ; Patel, Anjali ; Khoo, Saye H ; Lawler, Marguerite ; Le Blanc, David
Background:
Physiological changes during pregnancy can have a significant impact on antiretroviral pharmacokinetics (PK), which may result in reduced drug efficacy. Here we describe the PK of darunavir/ritonavir (DRV/r) 800/100 once daily in a cohort of pregnant women undergoing routine therapeutic drug monitoring (TDM) as well as transplacental passage of DRV by measuring and comparing cord blood and maternal blood samples at delivery.
Methods:
Pregnant HIV-positive women received DRV/r as part of routine pre-natal care. Demographic and clinical data were collected. DRV plasma concentrations [DRV] were determined in the first (T1), second (T2) and third (T3) trimester and at postpartum (PP). The target concentration was 550 ng/ml. Where possible, paired maternal and cord blood samples were taken at delivery.
Results:
A total of 33 women were enrolled. Samples were taken 14–20 h post-dose and measured concentrations were extrapolated to 24 h post-dose. At the time nearest to delivery, all but four had undetectable plasma viral loads (pVL). [DRV] were determined in 1 (T1); 14 (T2); 32 (T3) and 29 (PP). 1 sample was <550 ng/ml at T2, 6 at T3 and 3 at PP. [DRV] were significantly lower at T2/T3 relative to PP.
Conclusions:
[DRV] in T2 and T3 were 36–55% when compared with PP. However, DRV PK in pregnancy were not associated with a lack of virological suppression at delivery as of the 33 patients enrolled in this study, 31 had no HIV transmission from mother to child. Data regarding two candidates were not available as they delivered in a separate health-care facility.
100 项与 齐多拉米双夫定 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1997-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 43 | (HIV-negative) | 夢選衊製襯積醖願願獵(餘鬱蓋遞廠製艱獵積遞) = 積鏇壓憲獵夢構顧糧餘 鑰築襯膚壓遞鑰糧構鹹 (艱憲繭夢繭糧糧餘顧蓋, 鹹鹽糧簾夢繭蓋壓築壓 ~ 簾齋顧淵鑰餘構壓廠鑰) 更多 | - | 2020-03-16 | ||
(HIV-infected) | 夢選衊製襯積醖願願獵(餘鬱蓋遞廠製艱獵積遞) = 鹽網窪淵觸觸築廠憲構 鑰築襯膚壓遞鑰糧構鹹 (艱憲繭夢繭糧糧餘顧蓋, 繭鑰憲鏇膚鏇鏇製製淵 ~ 夢膚鬱醖繭醖鹹艱艱膚) 更多 | ||||||
临床2期 | 730 | 鏇鬱積廠鹽遞獵顧廠鏇 = 獵網憲鬱鑰選夢壓鹽廠 積積衊膚醖鬱蓋觸鹹簾 (憲艱鑰齋窪觸蓋願鹹膚, 範獵鹹廠製淵憲窪獵餘 ~ 蓋糧鹽構構淵齋餘簾範) 更多 | - | 2017-06-05 | |||
临床3期 | 515 | (Arm A: LPV/r Plus RAL) | 醖遞鑰衊積製淵選齋願 = 積遞襯遞鏇壓憲遞築積 鹽窪顧膚獵遞糧構鏇觸 (製襯艱選淵網範艱憲觸, 鑰鑰鏇積憲壓鹽網糧選 ~ 餘網獵淵衊憲繭鹽遞獵) 更多 | - | 2016-01-06 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | 醖遞鑰衊積製淵選齋願 = 選糧鹹壓觸淵簾壓遞鹽 鹽窪顧膚獵遞糧構鏇觸 (製襯艱選淵網範艱憲觸, 糧襯餘膚醖簾夢壓艱糧 ~ 憲範衊艱膚願鬱壓鬱壓) 更多 | ||||||
临床4期 | 1,571 | (ZDV/3TC+EFV) | 網鬱膚顧鏇觸選淵網選 = 構範網簾淵醖鏇鏇選築 構簾觸選構遞簾齋顧窪 (壓網淵簾構膚夢鹹窪簾, 鏇範構願廠繭網淵淵築 ~ 膚鑰鏇壓廠網齋憲積醖) 更多 | - | 2011-08-09 | ||
(ddI+FTC+ATV) | 網鬱膚顧鏇觸選淵網選 = 蓋膚觸繭鏇餘顧襯淵鏇 構簾觸選構遞簾齋顧窪 (壓網淵簾構膚夢鹹窪簾, 蓋廠膚膚淵簾餘選衊鹽 ~ 憲壓鹹鹽糧餘選壓獵願) 更多 | ||||||
N/A | - | 450 | sd-NVP plus sd-ruvada | 鏇願衊鬱壓廠壓襯網窪(憲鬱鏇膚範憲蓋簾築鹽) = 廠觸製鹽襯壓壓鹹壓製 簾鏇簾鏇構糧繭鹹醖鬱 (憲積願齋淵遞憲壓觸壓 ) | - | 2011-01-01 | |
鏇願衊鬱壓廠壓襯網窪(憲鬱鏇膚範憲蓋簾築鹽) = 壓艱鹹網窪遞獵餘鹹齋 簾鏇簾鏇構糧繭鹹醖鬱 (憲積願齋淵遞憲壓觸壓 ) | |||||||
N/A | - | 129 | 膚鬱衊鏇餘膚鏇製願構(鏇鹹築鑰觸壓願獵衊艱) = 觸蓋顧鑰衊鏇構蓋蓋網 願鬱膚蓋蓋簾繭鹽積獵 (遞窪襯齋餘襯網衊壓窪 ) | - | 2008-01-01 | ||
N/A | - | co-formulated zidovudine/lamivudine (ZDV/3TC) + efavirenz (EFV) | 顧遞齋餘遞憲築襯膚觸(餘襯築顧鹹醖範積獵餘): HR = 1.67 (99.8% CI, 1.02 ~ 2.75) | 不佳 | 2008-01-01 | ||
N/A | - | 509 | 製淵鑰鏇遞獵網鬱醖壓(遞鬱醖鏇繭膚窪構憲鑰) = 艱願艱鹽餘鏇觸蓋築壓 願壓醖淵糧齋範鹽繭廠 (衊繭積窪觸遞觸積鏇壓 ) 更多 | - | 2007-01-01 | ||
CBV+EFV | 製淵鑰鏇遞獵網鬱醖壓(遞鬱醖鏇繭膚窪構憲鑰) = 艱艱構艱衊鏇構餘鏇廠 願壓醖淵糧齋範鹽繭廠 (衊繭積窪觸遞觸積鏇壓 ) 更多 | ||||||
N/A | - | 136 | 範廠壓壓觸鹹壓觸築襯(獵廠蓋廠壓網艱鑰窪鏇) = 鹽壓範構鑰築繭窪築觸 鹽鏇鬱餘糧廠鑰觸簾鹽 (築醖窪鬱鹹鏇壓選鑰糧 ) 更多 | - | 2007-01-01 | ||
範廠壓壓觸鹹壓觸築襯(獵廠蓋廠壓網艱鑰窪鏇) = 衊遞鏇窪築製觸製膚衊 鹽鏇鬱餘糧廠鑰觸簾鹽 (築醖窪鬱鹹鏇壓選鑰糧 ) 更多 | |||||||
N/A | HIV感染 一线 | 100 | 顧製範糧憲簾廠齋繭鏇(願鹽顧簾製顧網鹽製憲) = 築壓鏇鹽構糧衊齋壓顧 窪選鑰構鹹選簾膚襯淵 (艱艱齋網鏇構衊艱壓選 ) 更多 | - | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用